Domain Therapeutics has named Youssef Bennani as chairman of the company's board, taking over from Sam Eletr.
Bennani currently serves as site head and VP of R&D at Vertex Pharmaceuticals' site in Laval, Quebec. Prior to this, he spent seven years as VP of drug innovation at Vertex .
“Dr Bennani joins us at a time when we intend to strengthen our role as a pharma industry partner and expand our internal pipeline,” said Pascal Neuville, board director and CEO of Domain.
This pipeline includes new drug candidates targeting G protein-coupled receptors. Domain has several partnerships involving these products, including one with Merck Serono in Parkinson's disease.
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....